157 related articles for article (PubMed ID: 31407255)
1. Prediction of clinical outcome by controlling nutritional status (CONUT) before allogeneic hematopoietic stem cell transplantation in myeloid malignancies.
Araie H; Kawaguchi Y; Okabe M; Lee Y; Ohbiki M; Osaki M; Goto M; Goto T; Morishita T; Ozawa Y; Miyamura K
Int J Hematol; 2019 Nov; 110(5):599-605. PubMed ID: 31407255
[TBL] [Abstract][Full Text] [Related]
2. Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34
Barba P; Ratan R; Cho C; Ceberio I; Hilden P; Devlin SM; Maloy MA; Barker JN; Castro-Malaspina H; Jakubowski AA; Koehne G; Papadopoulos EB; Ponce DM; Sauter C; Tamari R; van den Brink MRM; Young JW; O'Reilly RJ; Giralt SA; Perales MA
Biol Blood Marrow Transplant; 2017 Jan; 23(1):67-74. PubMed ID: 27789361
[TBL] [Abstract][Full Text] [Related]
3. Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort on Behalf of the Grupo Español de Trasplante Hematopoyetico.
Orti G; Sanz J; Bermudez A; Caballero D; Martinez C; Sierra J; Cabrera Marin JR; Espigado I; Solano C; Ferrà C; García-Noblejas A; Jimenez S; Sampol A; Yañez L; García-Gutiérrez V; Pascual MJ; Jurado M; Moraleda JM; Valcarcel D; Sanz MA; Carreras E; Duarte RF
Biol Blood Marrow Transplant; 2016 Mar; 22(3):584-8. PubMed ID: 26631751
[TBL] [Abstract][Full Text] [Related]
4. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
5. [Prognostic implications of hematopoietic cell transplantation-specific comorbidity index on non-relapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation].
Wang CY; Ren HY; Qiu ZX; Wang Y; Cen XN; Wang LH; Wang MJ; Xu WL; Wang WS; Li Y; Dong YJ; Ou JP; Liang ZY; Liu W; Wang Q
Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):659-63. PubMed ID: 23978015
[TBL] [Abstract][Full Text] [Related]
6. Clinical impact of the CONUT score and mogamulizumab in adult T cell leukemia/lymphoma.
Ureshino H; Kusaba K; Kidoguchi K; Sano H; Nishioka A; Itamura H; Yoshimura M; Yokoo M; Shindo T; Kubota Y; Ando T; Kojima K; Sueoka E; Kimura S
Ann Hematol; 2019 Feb; 98(2):465-471. PubMed ID: 30264165
[TBL] [Abstract][Full Text] [Related]
7. Bone Marrow WT1 Levels in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplasia: Clinically Relevant Time Points and 100 Copies Threshold Value.
Nomdedéu JF; Esquirol A; Carricondo M; Pratcorona M; Hoyos M; Garrido A; Rubio M; Bussaglia E; García-Cadenas I; Estivill C; Brunet S; Martino R; Sierra J
Biol Blood Marrow Transplant; 2018 Jan; 24(1):55-63. PubMed ID: 28939453
[TBL] [Abstract][Full Text] [Related]
8. Severe hypoalbuminemia at day 90 predicts worse nonrelapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome.
Kharfan-Dabaja MA; Chavez JC; Yu D; Zhu W; Fernandez-Vertiz EI; Perkins J; Shapiro J; Bookout R; Perez L; Fernandez HF; Komrokji RS; Lancet J; Brand L; Field T; Ayala E; Janssen W; List AF; Anasetti C
Biol Blood Marrow Transplant; 2011 Mar; 17(3):384-93. PubMed ID: 20655389
[TBL] [Abstract][Full Text] [Related]
9. Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing allo-RIC.
Barba P; Piñana JL; Martino R; Valcárcel D; Amorós A; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
Biol Blood Marrow Transplant; 2010 Mar; 16(3):413-20. PubMed ID: 19922807
[TBL] [Abstract][Full Text] [Related]
10. CD34
Barba P; Martino R; Zhou Q; Cho C; Castro-Malaspina H; Devlin S; Esquirol A; Giralt S; Jakubowski AA; Caballero D; Maloy M; Papadopoulos EB; Piñana JL; Fox ML; Márquez-Malaver FJ; Valcárcel D; Solano C; López-Corral L; Sierra J; Perales MA
Biol Blood Marrow Transplant; 2018 May; 24(5):964-972. PubMed ID: 29305194
[TBL] [Abstract][Full Text] [Related]
11. Impact of Obesity on Clinical Outcomes of Elderly Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies.
Voshtina E; Szabo A; Hamadani M; Fenske TS; D'Souza A; Chhabra S; Saber W; Drobyski WR; Hari P; Shah NN
Biol Blood Marrow Transplant; 2019 Jan; 25(1):e33-e38. PubMed ID: 30244105
[TBL] [Abstract][Full Text] [Related]
12. Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome.
Shaffer BC; Ahn KW; Hu ZH; Nishihori T; Malone AK; Valcárcel D; Grunwald MR; Bacher U; Hamilton B; Kharfan-Dabaja MA; Saad A; Cutler C; Warlick E; Reshef R; Wirk BM; Sabloff M; Fasan O; Gerds A; Marks D; Olsson R; Wood WA; Costa LJ; Miller AM; Cortes J; Daly A; Kindwall-Keller TL; Kamble R; Rizzieri DA; Cahn JY; Gale RP; William B; Litzow M; Wiernik PH; Liesveld J; Savani BN; Vij R; Ustun C; Copelan E; Popat U; Kalaycio M; Maziarz R; Alyea E; Sobecks R; Pavletic S; Tallman M; Saber W
J Clin Oncol; 2016 Jun; 34(16):1864-71. PubMed ID: 27044940
[TBL] [Abstract][Full Text] [Related]
13. Hypoalbuminemia at Day +90 Is Associated with Inferior Nonrelapse Mortality and Overall Survival in Allogeneic Hematopoietic Cell Transplantation Recipients: A Confirmatory Study.
Murthy HS; Sheets K; Kumar A; Nishihori T; Mina A; Chavez JC; Ayala E; Field T; Mathews J; Locke F; Perez L; Betts BC; Khimani F; Miladinovic B; Tsalatsanis A; Ochoa-Bayona JL; Alsina M; Fernandez H; Pidala J; Anasetti C; Kharfan-Dabaja MA
Biol Blood Marrow Transplant; 2018 Feb; 24(2):400-405. PubMed ID: 29032266
[TBL] [Abstract][Full Text] [Related]
14. The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation.
Solh MM; Solomon SR; Morris LE; Zhang X; Holland HK; Bashey A
Biol Blood Marrow Transplant; 2019 Mar; 25(3):606-612. PubMed ID: 30244109
[TBL] [Abstract][Full Text] [Related]
15. Enhanced labile plasma iron and outcome in acute myeloid leukaemia and myelodysplastic syndrome after allogeneic haemopoietic cell transplantation (ALLIVE): a prospective, multicentre, observational trial.
Wermke M; Eckoldt J; Götze KS; Klein SA; Bug G; de Wreede LC; Kramer M; Stölzel F; von Bonin M; Schetelig J; Laniado M; Plodeck V; Hofmann WK; Ehninger G; Bornhäuser M; Wolf D; Theurl I; Platzbecker U
Lancet Haematol; 2018 May; 5(5):e201-e210. PubMed ID: 29628397
[TBL] [Abstract][Full Text] [Related]
16. No benefit of hypomethylating agents compared to supportive care for higher risk myelodysplastic syndrome.
Sohn SK; Moon JH; Lee IH; Ahn JS; Kim HJ; Chung JS; Shin HJ; Park SW; Lee WS; Lee SM; Kim H; Lee HS; Kim YS; Cho YY; Bae SH; Lee JH; Kim SH; Song IC; Kwon JH; Lee YJ
Korean J Intern Med; 2018 Nov; 33(6):1194-1202. PubMed ID: 29232940
[TBL] [Abstract][Full Text] [Related]
17. Cytogenetic Evolution in Myeloid Neoplasms at Relapse after Allogeneic Hematopoietic Cell Transplantation: Association with Previous Chemotherapy and Effect on Survival.
Ertz-Archambault N; Kosiorek H; Slack JL; Lonzo ML; Greipp PT; Khera N; Kelemen K
Biol Blood Marrow Transplant; 2017 May; 23(5):782-789. PubMed ID: 28189903
[TBL] [Abstract][Full Text] [Related]
18. Clinical Utility of Wilms' Tumor 1 Monitoring in Patients with Myeloid Malignancy and Prior Allogeneic Hematopoietic Stem Cell Transplantation.
Ino K; Fuji S; Tajima K; Tanaka T; Okinaka K; Inamoto Y; Kurosawa S; Kim SW; Katayama N; Fukuda T
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1780-1787. PubMed ID: 28673850
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic hematopoietic stem cell transplant overcomes poor prognosis of acute myeloid leukemia with myelodysplasia-related changes.
Ikegawa S; Doki N; Kurosawa S; Yamaguchi T; Sakaguchi M; Harada K; Yamamoto K; Hino Y; Shingai N; Senoo Y; Watanabe K; Igarashi A; Najima Y; Kobayashi T; Kakihana K; Sakamaki H; Ohashi K
Leuk Lymphoma; 2016; 57(1):76-80. PubMed ID: 26084204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
